Multicenter study of cladribine in relapsing-remitting multiple sclerosis in patients over 50 years.
OBJECTIVE Cladribine is an oral immunomodulatory drug approved for the treatment of relapsing-remitting multiple sclerosis. However, evidence regarding its use in patients over 50 years is limited. The aim of the study was to evaluate the effectiveness and safety of cladribine in patients with relapsing-remitting multi...